CREST Syndrome

Differentiating between CREST syndrome (limited cutaneous systemic sclerosis) and diffuse systemic sclerosis is crucial for prognosis and management. While both conditions feature Raynaud's phenomenon, skin thickening in CREST syndrome is typically limited to the hands, forearms, feet, and face (distal to the elbows and knees). In contrast, diffuse systemic sclerosis involves skin thickening of the trunk and proximal extremities. Furthermore, CREST syndrome is characterized by calcinosis, Raynaud's, esophageal dysmotility, sclerodactyly, and telangiectasia, which are often less severe and progress more slowly compared to diffuse disease. Serological markers like anticentromere antibodies are highly suggestive of CREST, while anti-Scl-70 antibodies are associated with diffuse systemic sclerosis. Pulmonary involvement, such as interstitial lung disease, and significant renal crisis are more common and severe in diffuse disease. Consider implementing a thorough evaluation including physical examination, serological testing (anticentromere, anti-Scl-70, and ANA), pulmonary function tests, and high-resolution CT of the chest to guide your diagnosis and differentiate between the two. Explore how these findings can inform your treatment approach and improve patient outcomes.

Esophageal dysmotility is a frequent and debilitating complication in CREST syndrome. The primary issue is impaired esophageal peristalsis and lower esophageal sphincter tone, leading to gastroesophageal reflux disease (GERD), dysphagia, and aspiration. Evidence-based management strategies include lifestyle modifications such as small, frequent meals, avoiding late-night eating, and elevating the head of the bed. Pharmacological interventions include proton pump inhibitors (PPIs) for acid suppression and prokinetic agents like metoclopramide to improve esophageal motility. For patients with severe dysmotility refractory to medical therapy, consider implementing more invasive strategies such as endoscopic dilation or surgical myotomy. Regular monitoring for Barrett's esophagus through endoscopy is essential due to the increased risk in CREST patients. Learn more about the latest clinical guidelines for managing GERD and dysphagia in systemic sclerosis for a comprehensive approach.

Calcinosis cutis, a hallmark feature of CREST syndrome, presents as painful subcutaneous calcium deposits, commonly affecting the fingers, hands, and elbows. While the exact pathogenesis remains unclear, it is believed to involve vascular damage, tissue ischemia, and abnormal calcium metabolism. Diagnosis is primarily clinical, often confirmed by radiographic imaging (X-ray, CT) revealing calcium deposits. Management focuses on alleviating pain and preventing complications such as infection. Treatment options include topical therapies, analgesics, surgical removal for large or ulcerated lesions, and medications like diltiazem, which may inhibit calcium deposition. Regular wound care and infection prevention strategies are essential. Explore how early recognition and intervention can improve the quality of life for CREST patients with calcinosis cutis. Consider implementing a multidisciplinary approach involving rheumatologists, dermatologists, and potentially surgeons to optimize patient outcomes.